Will hawkish central banks derail biotech's bounce back?

Fears that delayed interest rate cuts could scupper biotech’s long-awaited recovery may be overstated, according to RTW’s Oliver Kenyon.

10 April 2026

Fears that delayed interest rate cuts could scupper biotech’s long-awaited recovery may be overstated, according to RTW’s Oliver Kenyon.

Stay informed about investment companies with our regular emails.

First name

Surname

Email address

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.